Zattarin Emma, Presti Daniele, Mariani Luigi, Sposetti Caterina, Leporati Rita, Menichetti Alice, Corti Chiara, Benvenuti Chiara, Fucà Giovanni, Lobefaro Riccardo, Ligorio Francesca, Provenzano Leonardo, Vingiani Andrea, Del Vecchio Marta, Griguolo Gaia, Sirico Marianna, Bernocchi Ottavia, Marra Antonio, Zagami Paola, Agostinetto Elisa, Jacobs Flavia, Di Mauro Pierluigi, Esposito Andrea, Giorgi Carlo Alberto, Lalli Luca, Boldrini Laura, Giacchetti Pier Paolo Berton, Schianca Ambra Carnevale, Guarneri Valentina, Pedersini Rebecca, Losurdo Agnese, Zambelli Alberto, Generali Daniele, Criscitiello Carmen, Curigliano Giuseppe, Pruneri Giancarlo, de Braud Filippo, Dieci Maria Vittoria, Vernieri Claudio
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
NPJ Breast Cancer. 2023 Apr 17;9(1):27. doi: 10.1038/s41523-023-00534-1.
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.
在接受一线内分泌治疗联合CDK 4/6抑制剂治疗的HR + /HER2-晚期乳腺癌（aBC）患者中，人表皮生长因子受体2（HER2）低表达状态是否具有预后意义仍不清楚。在评估的428例患者中，与HER2-0状态相比，HER2低表达状态与显著更差的无进展生存期（PFS）和总生存期（OS）独立相关。基于我们的研究结果，HER2低表达状态可能成为这种临床情况下一种新的预后生物标志物。
